by Annie De Groot | Mar 28, 2019 | News
THIS ORIGINAL ARTICLE WAS PUBLISHED IN PR NEWSWIRE. LINK TO THE ORIGINAL ARTICLE CAN BE FOUND HERE. NEW YORK, March 25, 2019 /PRNewswire/ — EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced that its abstract has been selected for...
by Annie De Groot | Mar 5, 2019 | Events
American Association for Cancer Research (AACR) Annual MeetingFriday, March 29th – Wednesday, April 3rdGeorgia World Congress CenterAtlanta, GeorgiaThank you to everyone who attended Dr. Richard’s presentation at AACR 2019. We hope you learned something...
by Annie De Groot | Feb 25, 2019 | Thinking Out Loud -Blog
What’s Wrong With This Picture?No, not that one!(But yes, our 20th birthday was last year)…This one: a recent article published in Natureabout a de novo IL-2 mimetic. Interleukin-2 (IL-2) is a potent anti-cancer treatment that stimulates the immune...
by Sarah Moniz | Jun 13, 2018 | Featured, News
NEW YORK CITY AND PROVIDENCE, RI., June 12, 2018 (BUSINESS WIRE) — EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced the closing of a $1.2M Bridge Financing. The investors include NextWaveBio, Morningside Venture Investments, Accelerate...
by Annie De Groot | Dec 3, 2017 | Thinking Out Loud -Blog
So, you say, why not? Why wait for Gritstone, BioNtec, Neon or even EpiVax Oncology when you can just DIY? If you can now sequence your own cancer mutanome (for about $5,000), and predict your own mutated epitopes using online tools, why not? Some cancer patients are...